|
|
Agendia News and Press Releases
For all media and investor relations inquiries, please contact:
Hans Herklots
Head of Corporate Communications
Telephone: +31 20 462 1557
Email: hans.herklots@agendia.com
|
Sort by Date
|
Sort by Article
|
|
06/04/10
|
Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
Researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia’s MammaPrint®, BluePrint™, and ColoPrint™ at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. The study results underpin the broad predictive and prognostic power of MammaPrint and highlight prospective and independently validated data on ColoPrint. Visitors can meet the Agendia team in booth #18018.
|
|
04/29/10
|
New Study Demonstrates Patients with High-Risk MammaPrint Profile Benefit from Chemotherapy
At the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test.
|
|
03/24/10
|
Agendia Launches BluePrint™ Expanding Breast Cancer Product Offering
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, March 24, 2010 – Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint®, and TargetPrint™, has been expanded with BluePrint ™ to report important additional information on tumor subtypes.
|
|
03/17/10
|
Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, February 9, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer. I-SPY is an initiative of the Biomarkers Consortium, a unique public-private partnership that includes the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH).
|
|
02/09/10
|
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, February 9, 2010 –Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive commercial samples of MammaPrint, its FDA-cleared breast cancer recurrence test.
|
|
